Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020

• DOI: 10.1001/jamanetworkopen.2021.35123
• Publication Date: 2021-11-18T16:21:13Z
• Authors: Alyson Haslam; Mark P. Lythgoe; Emma Greenstreet ...; Vinay Prasad
• Keywords: Odds; Excellence; Incremental cost-effectiveness ratio

Increasingly, cost-effectiveness analyses are being done to determine the value of rapidly increasing oncology drugs; however, this assumes that these unbiased.To analyze characteristics studies and associated with whether an drug is found be cost-effective.This retrospective cross-sectional study included 254 for 116 drugs were approved by US Food Drug Administration from 2015 2020.Each was analyzed incremental ratio per quality-adjusted life year, funding study, authors' conflict interest, threshold willingness-to-pay, what country's perspective analysis done, a National Institute Health Care Excellence had been done.The main outcome odds concluding cost-effective.There approvals country perspectives. Of perspectives, 132 (52%) US. Forty-seven 78 cost-effective shown improve overall survival, whereas 15 38 without survival. Having funded pharmaceutical company higher than (odds ratio, 41.36; 95% CI, 11.86-262.23).In greater would cost-effective. These findings suggest simply disclosing potential interest inadequate. We encourage independent groups.